Positive Phase 3 Results Evaluating Lumateperone for the Prevention of Relapse in Schizophrenia
New positive results demonstrate the efficacy and safety of lumateperone (Caplyta) 42 mg for the prevention of relapse in adult patients with schizophrenia.